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Emerging evidence indicates that somatic stem cells (SSCs) of different types prominently
contribute to endometrium-associated disorders such as endometriosis. We reviewed the
pertinent studies available on PubMed, published in English language until December 2014
and focused on the involvement of SSCs in the pathogenesis of this common gyne-
cological disease. A concise summary of the data obtained from in vitro experiments,
animal models, and human tissue analyses provides insights into the SSC dysregulation
in endometriotic lesions. In addition, a set of research results is presented supporting that
SSC-targeting, in combination with hormonal therapy, may result in improved control of the
disease, while a more in-depth characterization of endometriosis SSCs may contribute to
the development of early-disease diagnostic tests with increased sensitivity and specificity.
Key message: Seemingly essential for the establishment and progression of endometri-
otic lesions, dysregulated SSCs, and associated molecular alterations hold a promise as
potential endometriosis markers and therapeutic targets.
Keywords: somatic stem cells, endometriosis, pathogenesis, endometriosis markers, drug target
INTRODUCTION
Somatic stem cells (SSCs), also known as adult or tissue-specific
stem cells, play a key role in the regulation of adult tissue home-
ostasis and regeneration. They are undifferentiated cells with
high-proliferative potential that originate from postembryonic cell
lineages and share with the embryonic stem cells two fundamen-
tal features: self-renewal capacity and multidifferentiative poten-
tial (1). SSCs have been described in different tissues, including
the endometria of menstruating and non-menstruating mam-
malian species (e.g., rodents) (2). In highly regenerative human
endometrium, remodeling occurs during each menstrual cycle,
after resection, parturition, and in postmenopausal women using
hormone replacement therapy (3). Increasing evidence indicates
that rare endometrial stem cells (EnSCs), which include epithelial
and mesenchymal stem cells (MSCs), are responsible for endome-
trial remodeling and regeneration [reviewed in Ref. (2, 4, 5)].
Abbreviations: ABCG2, ATP-binding cassette transporter G2; Ang1, angiopoietin-
1; BM-MSC, bone marrow-derived mesenchymal stem cell; BrdU, 5-bromo-2′-
deoxyuridine; CD, cluster of differentiation; CFUs, colony-forming units; COX-2,
ciclo-oxigenase-2; CXCR4, C–X–C chemokine receptor type 4; EnSC(s), endome-
trial stem cell(s); EPC, endothelial progenitor cells; GDF3, growth differentiation
factor-3; IFNγ, interferon gamma; IL-1β, interleukin-1 beta; IL-6, interleukin-
6; IPO13, importin 13; LRCs, label-retaining cells; MDR, multi-drug resistance
genes; miRNA, microRNA; MMP-2, -3, -9, matrix metalloproteinases 2, 3, 9; MSC,
mesenchymal stem cell; NANOG, Nanog homeobox; OCT-4, octamer-binding tran-
scription factor 4; PCR, polymerase chain reaction; PDGF, platelet derived growth
factor; PRRs, pattern recognition receptors; SALL4, sal-like 4; SCF, stem cell fac-
tor; SDF-1α, stromal cell-derived factor 1 alpha; SOX2, sex-determining region
Y-box 2; SP, side-population cells; SSC(s), somatic stem cell(s); TCL1A, T-cell
leukemia/lymphoma protein 1A; UTF1, undifferentiated embryonic cell transcrip-
tion factor 1; VEGF, vascular endothelial growth factor; ZFP42, zinc finger protein
42 homolog.
Besides, bone marrow-derived stem/progenitor cells are also able
to incorporate themselves into the endometrium, contributing to
the vascular remodeling (6) or transdifferentiating into endome-
trial cells (7, 8). In parallel, emerging research results suggest
that SSCs of multiple types and their abnormalities substantially
contribute to endometrial disorders (5).
We review currently available data regarding the stem cell
involvement in endometriosis, giving particular attention to the
potential clinical integration of the knowledge stemming from
basic science research. Using the key words “stem cell” and
“endometriosis,” we performed a literature search in PubMed for
the publications written in English language until December 1st,
2014. We detected and analyzed 116 articles, and included 54 pub-
lications that strictly fit into the topic (descriptive analyses on
human tissues, studies in animal models of endometriosis, in vitro
assays, and previous reviews). The information from 15 additional
articles was incorporated for a more comprehensive contextual-
ization of the data, providing, for instance, the epidemiological
data on endometriosis, definitions of the terms used, and more
profound explanation of some concepts discussed in previously
selected 54 articles (Table 1).
STEM CELL-BASED THEORY ON THE PATHOGENESIS OF
ENDOMETRIOSIS
Endometriosis is a gynecological disease histologically charac-
terized by the development and growth of endometrium-like
lesions outside the uterine cavity. Hypothetical mechanisms that
give origin to the endometriosis lesions include retrograde men-
struation, lymphatic and vascular spread, as well as iatrogenic
implantation of endometrial cells, celomic metaplasia/induced
mesenchymal cell differentiation, and embryonic rests (2). As
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Table 1 | Publications included in the review.
Focus Reference
Original
studies
Reviews
Main data sources
(54 publications)
Stem/progenitor cells in
(endometrium and)
endometriosis
(8–39) (1–7, 40–54)
Supplementary
information sources
(15 publications)
Endometriosis
Epidemiology (55)
Molecular biology (56–59)
Angiogenesis (60, 61)
Animal model (62)
Biomarkers (63) (64)
Stemness markers (65, 66)
Stem/progenitor cells in
eutopic endometrium
(67) (68, 69)
none of these theories individually explains the etiology of all
endometriosis types, combined mechanisms, including still undis-
covered tissue-specific pathophysiological processes, have been
taken into account. Accumulating research data suggest that EnSCs
play critical roles in the remodeling and regeneration of the phys-
iological endometrium (1–5, 7, 9–11, 40–49). In parallel with
these observations, stem cells have been also considered to be
major players in the pathogenesis of endometriosis (1) and other
endometrium-associated diseases (5).
Endometrial stem cells are present in the endometrium basalis
(12) as well as in the menstrual blood (13). In women affected
by endometriosis, significantly increased basalis portion is shed
in the menstrual flow (11). Complementing the Simpson’s the-
ory of retrograde menstruation, it has been hypothesized that
dysregulation and dislocation of EnSCs through the retrograde
flux into the peritoneal cavity may result in the proliferation of
ectopic endometrium-like tissue (3). Such dislocation of EnSCs
may occur, in particular, in the women with obstructive malfor-
mations of lower genital tract. Rare neonatal retrograde uterine
bleeding that displaces stem/progenitor cells present in neonatal
endometrium may be in the root of early-onset endometrio-
sis (50, 51). Human endometrium side-population (SP) cells,
which supposedly involve EnSCs, were found capable to generated
endometrium-like tissue in immunocompromised NOD-SCID
mice upon transplantation beneath the kidney capsule (14). Since
EnSCs are expected to differentiate in concordance with their
microenvironment (i.e., EnSC niche conditions), the deposition
of endometrial fragments containing both EnSCs and the niche
cells is likely to be required in naturally occurring endometrio-
sis (1). Indeed, unfractionated human endometrial fragments
successfully grow in ectopic sites in many experimental models
(46, 62). As an alternative, dislocation of functionally aberrant
EnSCs may occur (1). By analogy, traumatic dislocation of EnSCs
to the myometrium and altered regulatory mechanisms of the
EnSC niche have been taken into consideration regarding the
pathogenesis of adenomyosis (3).
Furthermore, abnormal cell migration during organogenesis
and differentiation of the female reproductive tract, frequently
associated with aberrant expression of Wnt and/or Hox genes,
has been also hypothesized as a possible mechanism of the dis-
location of primordial cells (15, 52). After menarche, these cells
hypothetically give origin to the endometriosis lesions. Addition-
ally, engraftment of bone marrow-derived MSC was documented
in a mouse model of experimental endometriosis (15). Interest-
ingly, in the same experiment, the disease was associated with
reduced stem cell recruitment in eutopic endometrium. Thus,
not only the EnSCs but also extra-uterine stem cells, transported
in the blood or lymph, may contribute to the formation of
endometriotic lesions through the process of transdifferentiation
into endometrial cells (8, 15).
Taken together, different concepts have emerged with refer-
ence to the putative stem cell involvement in the pathogenesis
of endometriosis. As depicted in Figure 1, both endometrium
and extra-EnSC sources were suggested. The stem cell positioning
in the ectopic sites was mechanistically attributed to the plau-
sible pathophysiological events such as retrograde menstruation,
trauma, lymphovascular dissemination, or aberrant cell migration
during reproductive tract organogenesis. In all these scenarios,
abnormal stem cell regulation, associated with disease-favoring
genetic and epigenetic alterations, constitutes a decisive factor for
the disease onset.
EVIDENCES SUPPORTING STEM/PROGENITOR CELL
CONTRIBUTION TO ENDOMETRIOSIS
Beginning in the late 1990s, several studies appeared indicating
a monoclonal origin of ovarian endometrial cysts and individual
glands of peritoneal endometriotic lesions, which are, in contrast,
polyclonal (16–21). These data did not only suggest a single-cell
derivation of ovarian endometriomas but also the possibility that
multiple precursor of peritoneal lesions might develop from a sin-
gle stem/progenitor cell (2). Evidence-based consolidation of the
stem cell concept for pathogenesis of endometriosis has been sub-
sequently favored by different descriptive studies on patient tissues
and experiments performed in vitro or in animal models.
Putative SSCs have been identified in human and animal
endometrium through diverse methods focused on the stem cell
clonogenicity (i.e., colony formation capacity), label-retaining,
“side-population” phenotype, undifferentiation marker expres-
sion, or cellular differentiation (1–5, 7, 9–11, 40–49, 68, 69).
Briefly, clonogenicity is defined as a single-cell ability to pro-
duce a colony consisting of its daughter cells, which are identical
to the mother cell. Clonogenic or colony formation assays are
cell survival in vitro tests that examine the clonogenic ability of
every cell in a population. Since the colony-forming ability is a
major stem cell feature, observations of colony-forming activ-
ity within the epithelial as well as stromal cell populations of
endometrium have been indicative of putative stem/progenitor cell
presence (3, 48). The concept of SSCs as rarely dividing cells, which
retain a DNA synthesis label 5-bromo-2′-deoxyuridine (BrdU),
has been also used in endometrium studies. In contrast to the
label retention in the immature progenitors, BrdU is diluted in
more mature cells due to higher mitotic activity. By identifying
and characterizing endometrial label-retaining cells (LRCs), the
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FIGURE 1 | Stem cell-based concept of the pathogenesis of
endometriosis. (A) Endometriosis is a complex, multifactorial disease
that develops in persons with genetic susceptibility and in the presence of
various endogenous and/or environmental contributing factors. (B) Stem
cells, which give origin to the endometriosis lesions under
disease-favoring microenvironment conditions, may reach the ectopic sites
via different routes as such as retrograde menstruation, lymphovascular
dissemination, direct transplantation, migration and invasion, and
abnormal cell migration during organogenesis. Besides the uterus (i.e., the
eutopic endometrium containing endometrial stem cells, EnSCs, which
are altered in endometriosis patients), bone marrow may also contribute to
the endometriosis stem cell pool with its stem/progenitor cells (bone
marrow-derived mesenchymal stem cells, MSCs, and endothelial
progenitor cells, EPCs). (C) Endometriosis stem cells are dysfunctional
due to a range of genetic and epigenetic alterations, displaying increased
self-renewal, survival, and aggressive phenotype. (D) Upon the
establishment, growing lesions require and induce angiogenesis as well as
the vasculogenic blood vessel formation from EPCs. Together with
inflammation and innervation, vascularized growth of endometriosis
lesions results in the appearance of the disease clinical manifestations.
experiments using this approach did not only point the existence
but also the localization of putative SSCs in both endometrial
glands and stroma (68, 69). Identification of endometrial“SP”cells
has provided additional evidence (9). In flow cytometry, SP cells
represent a small cellular sub-population with dye-effluxing prop-
erties. These cells, identified in many tissues and found to exhibit
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some stem cell-like features, efflux DNA-binding dye Hoechst
33342 by the activity of the multi-drug resistance (MDR) genes
(e.g., ATP-binding cassette transporter G2, ABCG2). In the case of
endometrium, ABCG2+ cells have been demonstrated to reside
preferentially in the vessel wall of the endometrial small caliber
vessels, holding capacity to differentiate into glandular, stromal,
endothelial, as well as smooth muscle cells (9). Different methods
used for SSC identification and isolation result in the selection of
distinct cell population. Apparently, various SSC types exist. Their
phenotypes, functions, and hierarchical relationship remain to be
fully elucidated.
However, even before the first identification of the cellular pop-
ulations with the characteristics of SSCs in endometrium, Osuga
et al. documented in 2000, an increase in the concentration of
stem cell factor (SCF) in the peritoneal fluid of women with vs.
without endometriosis (22). SCF, also known as steel factor, is a
ligand of c-KIT receptor (i.e., c-KIT proto-oncogene product),
which is present on the surface of hematopoietic stem cells and
other immature cells (65). SCF binding to c-KIT promotes cell
survival, proliferation, and differentiation. In parallel with the
cellular differentiation, c-KIT expression decreases. This undiffer-
entiation marker was found up-regulated in various cancers (65),
as well as in the lesions of endometriosis (23). In addition, some
endometriotic lesions over-express T-cell leukemia/lymphoma
protein 1A (TCL1A) (24), a known marker of immature T- and
B-cells and another proto-oncogene causally associated with T-
cell leukemia in humans (66). Moreover, endometriosis lesions
sometimes over-express Musashi-1, a RNA-binding protein related
with the cell fate determination of neural and epithelial progen-
itor cells (21). Fundamentally important for the self-renewal of
embryonic stem cells, undifferentiated embryonic cell transcrip-
tion factor 1 (UTF1) (24), octamer-binding transcription factor
4 (OCT-4) (23), sex-determining region Y-box 2 (SOX2), and
Nanog homeobox (NANOG) (25) are additional undifferentia-
tion markers identified in ectopic endometrioid tissues. The list
of stemness-related genes enhanced in endometriosis is contin-
uously expanding with the identification of novel markers, such
as importin 13 (IPO13) (26). Collectively, the analyses of undif-
ferentiation markers strongly indicate the existence of immature,
undifferentiated progenitors in the endometriotic lesions.
In favor of this hypothesis, aberrant telomerase activity and
greater telomere content have been observed in endometriotic
lesions (56) and patient peripheral blood (27, 57). These find-
ings may be associated with the immortality of endometriosis
stem cells. Besides, Silveira et al. evidenced in a group of eight
women affected by endometriosis that chromosomal imbalances
were shared by epithelial and stromal cells of endometriosis lesions
collected from different anatomical structures of the same patient
(28). Oppositely, eutopic endometria of the studied women were
characterized by normal karyotypes. In the majority of cases, pos-
itive immunostaining for stemness-related markers was detected
in isolated epithelial and stromal cells from both eutopic endome-
tria and ectopic endometrium-like tissues. Thus, the study further
strengthened the hypothesis that endometriosis lesions have clonal
origin with the putative involvement of stem/progenitor cells.
Complementing the knowledge that arose from the analy-
ses of stemness-related markers in endometriosis, Chan et al.
performed in vitro functional assays and demonstrated that ovar-
ian endometriotic cysts contain a cellular subset that displays SSC
features: (1) colony-forming activity, (2) self-renewal in vitro, and
(3) multipotency (29). The study highlighted the presence of both
epithelial and stromal progenitor cells. Colony-forming activity
was observed in 0.09% of epithelial and 0.13% of stromal cells.
Purified epithelial cells as well as the stromal cells formed large
and small colony-forming units (CFUs). Exhibiting substantial
self-renewal ability, it was assumed that large epithelial and stromal
CFUs had originated from putative SSCs. On the other hand, small
CFUs propagated less than the large CFUs. This is consistent with
their hypothetical origin from transit amplifying cells which rather
differentiate than proliferate. In addition, epithelial small CFUs
expressed ovarian epithelial markers while it was only sporadically
observed in the large CFUs. Stromal CFUs expressed both fibrob-
last markers and, importantly, three SSC markers (SALL4-like
4, CD133, and Musashi-1). Finally, the multipotency of stromal
large CFUs was proven since they were able to differentiate into
four mesenchymal lineages when cultured in appropriate media.
Although the identification of stem cells through in vitro assays
should be critically scrutinized due to the changes in cell biol-
ogy that may occur under artificial experimental conditions, Chan
et al. made with this study a significant step forward in addressing
the involvement of stem cells in the formation of endometriotic
lesions.
A growing body of evidence also indicates that bone marrow-
derived MSC and endothelial progenitor cells (EPCs) contribute
to the pathogenesis of endometriosis (10, 30, 31, 53). Cyclic repop-
ulation of endometrium with bone marrow-derived stem cells
probably represents a physiologic process, being in part respon-
sible for the stromal regeneration. Although uncommonly, these
cells can transdifferentiate into epithelial cells (<0.01%) (7). By
analogy, ectopic transdifferentiation might give origin to some
endometriotic lesions. Bone marrow-derived MSCs that have
previously colonized endometrium may be displaced by retro-
grade menstruation while direct mobilization of circulating MSCs
to the ectopic sides may be driven by a combination of mul-
tiple chemoattractants. Thereafter, MSC survival, self-renewal,
and lineage-commitment occur depending on the environmen-
tal conditions. Hypothetical promoters of ectopic transdifferen-
tiation include endometriosis-associated hormonal and cytokine
abnormalities. Serum of women with endometriosis possesses fac-
tors that enable MSC transformation into endometrial-like cells
and glands (30). In vitro, MSCs cultured with sera of women
with mild, moderate, and severe endometriosis differentiated into
endometrial-like cells and the differentiation rate increased among
the three groups from 30± 25.8% (mild disease) to 45± 29.9%
(moderate endometriosis) and 75± 37.9% (severe disease form)
(30). In vivo, in hysterectomized mice, bone marrow MSCs showed
the ability to engraft endometrial implants, while in the women
transplanted with male bone marrow, donor MSCs, recognizable
by the Y chromosome, generated endometrium de novo (10).
Although ectopic transdifferentiation might sporadically lead to
the onset of endometriosis, bone marrow-derived MSCs rather
contribute to the growth than initiate the endometriotic lesion.
As presented with more details below, the expression of pro-
inflammatory cytokines, migration markers, and pro-angiogenic
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factors is increased in ectopic vs. eutopic MSCs (32, 33). Despite
the fact that the grade of MSC contribution to the lesion prolifera-
tion requires further clarification, these cells participate in abnor-
mal immune responses and are capable to enhance endometriosis-
driven neovascularization. Sakr et al. have demonstrated the shift
of MSC engraftment from uterine endometrium to the lesions in
a mouse model (15). To promote its development, endometrio-
sis recruits MSCs, competing with eutopic endometrium for the
supply of bone marrow-derived cells. In this way, endometriosis
additionally interferes with endometrial regeneration, function,
and fertility.
Regarding the bone marrow-derived EPCs, up to 37% of the
endothelium in the endometriotic lesions originates from these
cells (53). Independent of the exact cause(s) and mechanism(s)
that lead to the establishment of endometriosis, the growth of its
lesions require neovascularization (6, 34, 35). As we and others
previously and extensively reviewed (53, 60, 61), endometrio-
sis triggers the angiogenic switch, i.e., the imbalance between
up-regulated pro-angiogenic stimuli and suppressed angiogenic
inhibitors. Sprouting of new capillary vessels from pre-existing
vasculature (angiogenesis) as well as de novo generation of blood
vessels from undifferentiated progenitors (vasculogenesis) main-
tain the endometriotic lesions and promote their growth (34–37,
53). In C57BL/6 mice, the disease did not increase the level of EPCs
in the blood, bone marrow, and spleen (37). However, vasculogenic
establishment of vessel networks from EPCs was documented to
represent an integral process in the pathogenesis of endometrio-
sis (37, 53). Endometriotic lesions show increased expression of
stromal-derived factor 1 alpha (SDF-1α) and vascular endothelial
growth factor (VEGF) (61), which are the main EPC chemoat-
tractant and mitogen, respectively. Hypoxia, inflammation, tissue
injury, and estrogen receptor expression promote the EPC mobi-
lization and recruitment (61). EPCs contribute to the vascular
network extension, especially in the initial stage of endometriosis
establishment. Importantly, pharmacological treatments that sup-
press EPCs, inhibit the lesion growth in endometriosis-bearing
mice (37, 53).
To sum up, ectopic endometrium-like tissues, in both animal
models and women affected with endometriosis, contain cellular
subpopulations exhibiting stem cell characteristics as indicated by
specific gene expression and/or in vitro functional assays. Bone
marrow stem/progenitor cells are actively present as well. Further
characterization (genetic, phenotypic, and functional) of putative
endometriosis initiating (stem/progenitor) cells is required while
their ability to form endometriosis lesions in vivo will be the ulti-
mate proof. Even though the stem cell is a major player, not only
the presence of such a cell but also its complex microenvironment
(niche) and other contributing factors/pathophysiological events
are likely to be essential in the establishment of endometriosis
(Figure 1).
DISTINGUISHING STEM CELL CHARACTERISTICS IN
ENDOMETRIOSIS
Although endometriosis-associated stem/progenitor cells remain
to be fully characterized, currently available data indicate that they
are genetically and phenotypically different in comparison with
their physiological analogs. The stem cells from lesions vs. eutopic
endometrium possess some distinguishing features while the dif-
ferences have been also identified between eutopic stem cells from
affected vs. disease-free women.
First of all, some stemness-related genes are preferentially
expressed in endometriosis lesions (e.g., UTF1, TCL1A, ZFP42,
and SALL4) and other undifferentiation markers (e.g., GDF3)
show higher frequency in eutopic endometrium (24). This indi-
rectly suggests that the mechanisms determining the self-renewal
rate and stem cell fate are dysregulated in endometriosis. Conse-
quently, altered stem cell behavior favors the disease onset. Known
chromosomal aberrations, impaired DNA methylation, histone
modifications, and imbalance of microRNA (miRNA) expression
that are associated with the phenotypic changes of endometrio-
sis stem cells have been recently reviewed by Forte et al. (40).
Particularly, intriguing findings arose from the studies on miRNA
imbalances. Naturally occurring miRNAs are single-stranded non-
coding small RNA molecules that function as post-transcriptional
gene repressors contributing, in this way, to the determination
of cell identity and fate (58). Their alterations have been docu-
mented in endometriotic lesions by real-time reverse transcription
PCR, TaqMan real-time PCR, and microarrays (40). Dysregulated
miRNAs apparently influence the endometriosis stem cell pheno-
type in various manners. For instance, impaired miR-145 function,
observed in endometriosis patients, promotes the stemness itself
and enhances the stem cell invasiveness (58) while down-regulated
miRNA-199a-5p contributes to the endometriosis progression
by promoting pro-angiogenic factor production by endometrial
MSCs (34).
Despite the complexity of known and unknown molecu-
lar phenomena underlying the phenotypic changes exhibited
by endometriosis stem cells, these changes involve five main
functional alterations: increases proliferation, migration, adhe-
sion/invasiveness, pro-angiogenic factor production, and dys-
regulated expression of certain immune modulators (13, 31,
33, 36, 38, 59). In two independent studies, Kao et al. (31)
and Moggio et al. (36) evidenced a higher proliferative, migra-
tory, and pro-angiogenic potential of ectopic MSCs in com-
parison with the eutopic MSCs from the same patient or con-
trol MSCs from women without endometriosis. Kao et al.
(33) equally witnessed the ectopic MSC to present augmented
invasiveness. These findings coincided with significantly higher
interleukin-1 beta (IL-1β) and ciclo-oxigenase-2 (COX-2) lev-
els in ectopic MSCs compared with eutopic MSCs. Additionally,
treatment with a COX-2 inhibitor induced apoptosis and sup-
pressed migration and invasiveness of adenomyosis MSCs, but
not of eutopic MSCs (38). Thus, eutopic and ectopic MSCs
are substantially different in terms of functionality. A recent
study compared eutopic and ectopic MSCs by analyzing their
phenotypes and gene expression of pattern recognition recep-
tors (PRRs), pro- and anti-inflammatory cytokines, migration
markers, and angiogenesis factors (32). The findings indicated
increased levels of PRRs such as toll-like receptors and col-
lectins, down-regulated anti-inflammatory TGFβ and increased
transcription of pro-inflammatory cytokines (IL-6, IFNγ), migra-
tion markers (MMP-2, -3, -9), and pro-angiogenic VEGF in
ectopic vs. eutopic MSCs. These results suggest that patho-
genic behavior of ectopic MSCs may be partially responsible for
www.frontiersin.org January 2015 | Volume 1 | Article 51 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Djokovic and Calhaz-Jorge Stem cells in endometriosis
attenuated immunosuppression and enhanced angiogenesis in
endometriosis.
Furthermore, menstrual blood-derived stromal stem cells from
endometriosis patients vs. healthy women possess altered mor-
phological features, higher CD9, CD10, and CD29 expression,
increased proliferation potential and invasiveness, and distinct
ability to express certain immune modulators when co-cultured
with allogeneic peripheral blood mononuclear cells (13). If we
accept that retrograde menstruation is a major mechanism that
disseminates endometrial cells to the peritoneal cavity, these data
may explain why endometriosis does not affect all women with ret-
rograde menstrual flux, but only some of them (those with altered
stem cell function). More broadly, impaired stem cell function
is detrimental, regardless the mechanism used by endometrium-
or bone marrow-derived stem cells to engraft the ectopic sites.
Increased survival, resistance, and phenotypic shift to a more
aggressive behavior are absolutely essential as far as currently
available evidences imply.
Finally, highly variable extension and clinical expression of
endometriosis could be related with the type of dysfunctional stem
cell responsible for its establishment. There are distinct differences
between EnSCs and bone marrow-driven MSCs. Both EnSCs and
MSCs produce immune-modulatory effects, but they show sig-
nificant differences in many immune/inflammatory pathways at
the protein and transcriptome levels (67). A number of other,
stemness- and cancer-related genes are differentially expressed
between these cells. Regarding the pro-angiogenic potential, MSCs
express higher levels of VEGF while EnSCs express substan-
tially higher levels of platelet derived growth factor (PDGF) and
angiopoietin-1 (Ang1) (67). This implies that EnSCs are more
angiogenic than MSCs since they are capable to trigger alterna-
tive angiogenic pathways. Specific stem cell type or even sub-
type that initiates and/or predominantly mediates endometriosis
development may be indeed decisive with respect to the evo-
lution and clinical manifestations of the disease. The invasive-
ness of endometriosis hypothetically increases with the increase
of the initiating cell aggressiveness, immune-modulatory, and
pro-angiogenic abilities.
CLINICAL PERSPECTIVES
Endometriosis affects approximately 8% of women of the repro-
ductive age (55), represents a major cause of chronic pelvic pain
and female infertility, and tremendously burdens the health sys-
tems around the world. Currently, two major problems hinder the
medical assistance to the women suffering from endometriosis:
the lack of appropriate biomarkers useful in early diagnosis and
the inexistence of conservative (medical) treatments with long-
lasting effect. Further characterization of the stem cell populations
in endometriosis is challenging and may open up possibilities
for rational development of novel and improved diagnostic and
therapeutic strategies.
Non-invasive tests are greatly needed for the early detection
of endometriosis in women suffering of chronic pain and/or
infertility with normal ultrasound findings. A test based
on the use of 28 potential markers has been recently proven as
a highly sensitive and specific tool to establish the diagnosis of
ultrasound-undetectable endometriosis (63). Complementing
this encouraging, but complex multi-marker approach, it will
be interesting to assess whether the blood levels of circulating
stem/progenitor cells are specifically different in patients to serve
as indicators of endometriosis and/or treatment efficacy. Increased
blood levels of EPCs or MSCs have been evidenced in some animal
models (53), but still there is no consistent overall information
(35). The tests of peripheral blood miRNA levels may be also
useful. As previously stated, important miRNA alterations have
been documented in endometriosis, including those associated
with stem cell dysfunction. In contrast to the serum proteins,
circulating miRNAs, as nucleic acids, can be amplified. Conse-
quently, their alterations may be detected with better sensitivity
and specificity (64).
Regarding the therapeutic usefulness, targeting stem cells
may be beneficial in accordance with their fundamental role in
endometriosis as well as with few seminal, but significant exper-
imental results. Potential usefulness of the SSCs from eutopic
endometrium has been already demonstrated in the treatment
of several chronic diseases (e.g., diabetes and Parkinson’s dis-
ease) (54). In contrast to these clinical conditions wherein EnSCs
may be engaged to provide specific differentiated cells and tissue
regeneration, suppression of stem cell recruitment and activity is
required in endometriosis. In a mouse model of endometriosis, a
selective estrogen receptor modulator bazedoxifene, administered
with conjugated estrogens, dramatically reduced the recruitment
of bone marrow-derived MSCs to the lesions, promoted MSC
engraftment in eutopic endometrium and resulted in regression
of endometriosis (15). Some constituents of tobacco smoke also
impair the stem cell influx to endometriosis lesions (39); however,
their pharmacological formulation is not yet available. Moreover,
sorafenib, a tyrosine kinase inhibitor and potent VEGF signal-
ing suppressor approved for the treatment of different cancer
types (60), was found able to inhibit endometriosis MSC pro-
liferation, migration, and pro-angiogenic phenotype (36), while
AMD3100, an antagonist of SDF-1α/CXCR4 signaling, decreased
both EPC number and vascular density in murine intraperitoneal
endometriotic lesions (37). Although few in number, all of these
concrete examples imply that stem cell targeting, in combination
with hormonal therapies, may contribute to more effective medical
treatment and prevention of relapses in endometriosis-affected
women. The strategies that will certainly deserve consideration in
future research include targeting of altered molecular mechanisms
in and outside the endometriosis stem cells, which promote their
recruitment, adhesion, survival, self-renewal, and pro-angiogenic
behavior.
CONCLUSION
The involvement of different kinds of SSCs in pathogenesis
of endometriosis and their dysfunction have become increas-
ingly evident. With the stem cell-based concept, it is possible
to integrate most of previously proposed theories regarding the
pathogenesis of endometriosis in a single and meaningful sys-
tem. A more in-depth comprehension of distinguishing stem cell
characteristics and altered regulation in this prevalent disease is
needed. Such research could contribute to the development of new
and improved diagnostic and therapeutic modalities for patients
suffering from endometriosis.
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